216 related articles for article (PubMed ID: 19724689)
1. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.
Gust KM; Hofer MD; Perner SR; Kim R; Chinnaiyan AM; Varambally S; Moller P; Rinnab L; Rubin MA; Greiner J; Schmitt M; Kuefer R; Ringhoffer M
Neoplasia; 2009 Sep; 11(9):956-63. PubMed ID: 19724689
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue.
Korkes F; de Castro MG; de Cassio Zequi S; Nardi L; Del Giglio A; de Lima Pompeo AC
BJU Int; 2014 May; 113(5):822-9. PubMed ID: 24053431
[TBL] [Abstract][Full Text] [Related]
3. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.
Greiner J; Ringhoffer M; Taniguchi M; Schmitt A; Kirchner D; Krähn G; Heilmann V; Gschwend J; Bergmann L; Döhner H; Schmitt M
Exp Hematol; 2002 Sep; 30(9):1029-35. PubMed ID: 12225794
[TBL] [Abstract][Full Text] [Related]
4. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.
Giannopoulos K; Li L; Bojarska-Junak A; Rolinski J; Dmoszynska A; Hus I; Greiner J; Renner C; Döhner H; Schmitt M
Int J Oncol; 2006 Jul; 29(1):95-103. PubMed ID: 16773189
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.
Greiner J; Li L; Ringhoffer M; Barth TF; Giannopoulos K; Guillaume P; Ritter G; Wiesneth M; Döhner H; Schmitt M
Blood; 2005 Aug; 106(3):938-45. PubMed ID: 15827130
[TBL] [Abstract][Full Text] [Related]
6. Redox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors.
Yang C; Li C; Zhang P; Wu W; Jiang X
Theranostics; 2017; 7(6):1719-1734. PubMed ID: 28529647
[TBL] [Abstract][Full Text] [Related]
7. The Role of CD44 and RHAMM in Endometrial (Endometrioid Type) Cancer: An Immunohistochemical Study.
Klarić M; Haller H; Brnčić Fischer A; Babarović E; Prijić A; Eminović S
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):606-612. PubMed ID: 29734248
[TBL] [Abstract][Full Text] [Related]
8. [RHAMM (receptor hyaluronan-mediated motility)-target peptides induce apoptosis in prostate cancer cells].
Akentieva NP; Shushanov SS
Vopr Onkol; 2016; 62(3):514-8. PubMed ID: 30463110
[TBL] [Abstract][Full Text] [Related]
9. The Receptor for Hyaluronan-Mediated Motility (CD168) promotes inflammation and fibrosis after acute lung injury.
Cui Z; Liao J; Cheong N; Longoria C; Cao G; DeLisser HM; Savani RC
Matrix Biol; 2019 May; 78-79():255-271. PubMed ID: 30098420
[TBL] [Abstract][Full Text] [Related]
10. Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines.
Chakrabarti R; Robles LD; Gibson J; Muroski M
Cancer Genet Cytogenet; 2002 Dec; 139(2):115-25. PubMed ID: 12550771
[TBL] [Abstract][Full Text] [Related]
11. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
12. The small leucine rich proteoglycan fibromodulin is overexpressed in human prostate epithelial cancer cell lines in culture and human prostate cancer tissue.
Reyes N; Benedetti I; Bettin A; Rebollo J; Geliebter J
Cancer Biomark; 2016; 16(1):191-202. PubMed ID: 26600400
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronan (HA) interacting proteins RHAMM and hyaluronidase impact prostate cancer cell behavior and invadopodia formation in 3D HA-based hydrogels.
Gurski LA; Xu X; Labrada LN; Nguyen NT; Xiao L; van Golen KL; Jia X; Farach-Carson MC
PLoS One; 2012; 7(11):e50075. PubMed ID: 23166824
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-associated protein in human oral squamous cell carcinomas.
Shigeishi H; Fujimoto S; Hiraoka M; Ono S; Taki M; Ohta K; Higashikawa K; Kamata N
Int J Oncol; 2009 Jun; 34(6):1565-71. PubMed ID: 19424574
[TBL] [Abstract][Full Text] [Related]
15. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.
Willemen Y; Van den Bergh JM; Bonte SM; Anguille S; Heirman C; Stein BM; Goossens H; Kerre T; Thielemans K; Peeters M; Van Tendeloo VF; Smits EL; Berneman ZN
Oncotarget; 2016 Nov; 7(45):73960-73970. PubMed ID: 27659531
[TBL] [Abstract][Full Text] [Related]
16. Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.
Koelzer VH; Huber B; Mele V; Iezzi G; Trippel M; Karamitopoulou E; Zlobec I; Lugli A
Hum Pathol; 2015 Nov; 46(11):1573-81. PubMed ID: 26351067
[TBL] [Abstract][Full Text] [Related]
17. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.
Lin B; Utleg AG; Gravdal K; White JT; Halvorsen OJ; Lu W; True LD; Vessella R; Lange PH; Nelson PS; Hood L; Kalland KH; Akslen LA
Clin Cancer Res; 2008 Mar; 14(5):1397-406. PubMed ID: 18316561
[TBL] [Abstract][Full Text] [Related]
18. Frequency of expression of RHAMM/CD168 in Egyptian patients with CML.
Gouda HM; Abdel Mohsen MM
J Egypt Natl Canc Inst; 2009 Jun; 21(2):93-9. PubMed ID: 21057560
[TBL] [Abstract][Full Text] [Related]
19. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells.
Hamilton SR; Fard SF; Paiwand FF; Tolg C; Veiseh M; Wang C; McCarthy JB; Bissell MJ; Koropatnick J; Turley EA
J Biol Chem; 2007 Jun; 282(22):16667-80. PubMed ID: 17392272
[TBL] [Abstract][Full Text] [Related]
20. Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression.
Choi S; Wang D; Chen X; Tang LH; Verma A; Chen Z; Kim BJ; Selesner L; Robzyk K; Zhang G; Pang S; Han T; Chan CS; Fahey TJ; Elemento O; Du YN
Mol Cancer; 2019 May; 18(1):92. PubMed ID: 31072393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
